Discovery

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 5, 2023
Cancer, Clinical trial, Joint, Wind, MRI, Fatty liver disease, Pharmacokinetics, GIPR, CML, ALL, NASH, THR, Inflation, Patient, Discovery, DUET, Safety, CT1, Webcast, Obesity, Conference, IRA, FXR, Pharmaceutical industry, Fine chemical, Medical imaging

FOSTER CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will provide an update on its pipeline and strategic priorities for 2023 during the Company’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023 at 9:00am PT.

Key Points: 
  • “2022 was a transformative year for Terns as we made important steps forward in our commitment to provide better, new medicines to people battling diseases with significant unmet medical needs.
  • “We expect 2023 to be an important year for Terns as we assess key inflection points for our clinical programs.”
    “Prior to our two recent financings, our cash runway supported three key clinical readouts from our three lead programs into 2025.
  • As such, it pains me to have to forsake my fellow cancer fighters in the United States because of economic policies that stifle medical innovation.
  • A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

Retrieved on: 
Friday, January 6, 2023
Research, Neurology, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Drug discovery, Research, Patient, NYSE, Discovery, ABBV, Therapy, Sale, Neoplasm, Pharmaceutical industry, AbbVie, Immunome

“Partnering with Immunome represents AbbVie’s commitment to developing and commercializing novel treatment approaches for solid tumors,” said Steve Davidsen, Ph.D., vice president, oncology discovery research, AbbVie.

Key Points: 
  • “Partnering with Immunome represents AbbVie’s commitment to developing and commercializing novel treatment approaches for solid tumors,” said Steve Davidsen, Ph.D., vice president, oncology discovery research, AbbVie.
  • “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates.
  • We look forward to utilizing their Discovery Engine to enhance our existing oncology pipeline.”
    “This collaboration with AbbVie, a true leader in the development and commercialization of oncology therapeutics, demonstrates the strength of Immunome’s Discovery Engine,” said Purnanand Sarma, Ph.D., president and CEO of Immunome.
  • “AbbVie shares our vision of harnessing the power of the human immune response to yield novel and first-in-class therapeutics that represent a shift in the cancer discovery paradigm.

Roku Surpasses 70 Million Active Accounts Globally

Retrieved on: 
Thursday, January 5, 2023
Audio, Video, Hardware, TV and Radio, Online, Consumer Electronics, Technology, Carriers and Services, Entertainment, Universe, Miss Universe, TI-84 Plus series, Discovery, AMC, Roku, Roku, Inc., Multimedia, The Great American Baking Show, Paramount, EMarketer, AMC Networks, Lionsgate, Television, Nielsen, Q4

Today, Roku, Inc. (NASDAQ: ROKU) announced that the number of global active accounts now exceeds 70 million.

Key Points: 
  • Today, Roku, Inc. (NASDAQ: ROKU) announced that the number of global active accounts now exceeds 70 million.
  • Active accounts as of Q4 2021 was 60.1 million.
  • View the full release here: https://www.businesswire.com/news/home/20230105005606/en/
    Roku celebrates 70 million active accounts.
  • For more information on Roku and The Roku Channel, please visit www.roku.com .

Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases

Retrieved on: 
Thursday, January 5, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Patent, Neurodegeneration, MBA, Development, Discovery, Quinazolinone, Therapy, Dementia, AD, Caregiver, Pharmaceutical industry

“We are very pleased that the USPTO has issued this important patent allowing us to build on our existing patent estate in a thoughtful and strategic manner,” said William Erhardt, M.D., President and Head of Development & Operations at Oligomerix.

Key Points: 
  • “We are very pleased that the USPTO has issued this important patent allowing us to build on our existing patent estate in a thoughtful and strategic manner,” said William Erhardt, M.D., President and Head of Development & Operations at Oligomerix.
  • “With this patent in place, we have enhanced the value of our portfolio, including our lead candidate OLX-07010 which will begin first-in-human clinical trials soon.”
    According to the Alzheimer’s Association, more than 6.5 million Americans suffer from AD.
  • Furthermore, the current cost for AD is $321 billion and projected to be more than $1 trillion by 2050.
  • “The issuance of the ‘766 patent supports our continued work aimed at blocking tau self-association to prevent downstream damage associated with neurodegeneration and dementias,” said James Moe, Ph.D., MBA, CEO and Head of Discovery and Strategy at Oligomerix.

KLDiscovery Launches ‘Review Manager’ Certification Program at Nebula Academy

Retrieved on: 
Wednesday, January 18, 2023
Legal, Technology, Professional Services, Software, Other Education, Training, Data Management, Other Professional Services, Education, Student, Data management, Discovery, Senior, Machine learning

KLDiscovery Inc. (“KLDiscovery” or the “Company”), a leading global provider of data management, information governance, eDiscovery, and advisory services solutions, is pleased to announce the launch of the latest certification course at its online Nebula Academy.

Key Points: 
  • KLDiscovery Inc. (“KLDiscovery” or the “Company”), a leading global provider of data management, information governance, eDiscovery, and advisory services solutions, is pleased to announce the launch of the latest certification course at its online Nebula Academy.
  • This course builds on existing foundational skillsets by teaching users to handle complex review and production tasks in Nebula.
  • Course topics include:
    As Nebula has seen exponential growth in recent years, so too has Nebula Academy.
  • With thousands of enrolled students and awarded certifications, Nebula Academy has made a tremendous impact on the user community at-large.

Papulopustular Rosacea Drug Pipeline Landscape Report 2022 Featuring Key Players - Timber Pharmaceuticals, Dermata Therapeutics, CAGE Bio, Promius Pharma, Alfasigma, BioMimetix - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Skin, Clinical trial, Acne, News, NDA, Minocycline, Acquisition, Discovery, Safety, II, Therapy, Environment, Pharmaceutical industry, Cosmetics, Rosacea

This "Papulopustular Rosacea- Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Papulopustular Rosacea pipeline landscape.

Key Points: 
  • This "Papulopustular Rosacea- Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Papulopustular Rosacea pipeline landscape.
  • A detailed picture of the Papulopustular Rosacea pipeline landscape is provided which includes the disease overview and Papulopustular Rosacea treatment guidelines.
  • The assessment part of the report embraces, in depth Papulopustular Rosacea commercial assessment and clinical assessment of the pipeline products under development.
  • It also analyses Papulopustular Rosacea therapeutic drugs key players involved in developing key drugs.

Anorexia Nervosa Drug Pipeline Landscape Report 2022: Therapeutic Assessment of Key Products Such as Psilocybin and Ibogaine - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Pharmaceutical, Health, Clinical Trials, Psilocybin, Clinical trial, Research, News, NDA, Ibogaine, Disease, Acquisition, Discovery, Safety, II, Therapy, Pharmaceutical industry, Anorexia nervosa

This "Anorexia Nervosa - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anorexia Nervosa pipeline landscape.

Key Points: 
  • This "Anorexia Nervosa - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anorexia Nervosa pipeline landscape.
  • "Anorexia Nervosa - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Anorexia Nervosa pipeline landscape is provided which includes the disease overview and Anorexia Nervosa treatment guidelines.
  • The assessment part of the report embraces, in depth Anorexia Nervosa commercial assessment and clinical assessment of the pipeline products under development.

Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Health, Pharmaceutical, Aspergillosis, Clinical trial, MDR, European Medicines Agency, QIDP, Breakthrough therapy, Research, III, News, NDA, Candida auris, Auris, Disease, Acquisition, Discovery, Infection, Drug of last resort, FDA, Therapy, Goodyear F2G Corsair, II, IV, Pharmaceutical industry, Aspergillus, Pneumocystidomycetes

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
  • The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D.

BYRON ALLEN'S ALLEN MEDIA DIGITAL HIRES HAROLD MORGENSTERN AS PRESIDENT OF DIRECT ADVERTISING SALES & PARTNERSHIPS

Retrieved on: 
Wednesday, January 4, 2023
Partnership, Advertising, British Academy of Film and Television Arts, Communication, Science, Pluto TV, SVOD, AMG, Sport, Entertainment Studios, OTT, Marketing, Digital, Pluto, AVOD, Acquisition, Discovery, State university system, Weather, ViacomCBS, HBCU, The College at Brockport, State University of New York, Senior, Video game, Buffalo, PLEX, Northwestern University

LOS ANGELES, Jan. 4, 2023 /PRNewswire/ -- Byron Allen's Allen Media Group (AMG) proudly announces the hiring of Harold Morgenstern to the position of President of Direct Advertising Sales & Partnerships. In this newly-created role, Morgenstern will oversee all direct digital advertising sales, brand sponsorships, and revenue partnerships for the AMG free-streaming AVOD services HBCU GO, SPORTS.TV, THEGRIO, THE WEATHER CHANNEL EN ESPAÑOL, THE WEATHER CHANNEL STREAMING APP, and LOCAL NOW--the free-streaming AVOD service, which delivers real-time, hyper-local news, weather, traffic, sports, entertainment and lifestyle content. Morgenstern will be based at the AMG offices in New York City.

Key Points: 
  • LOS ANGELES, Jan. 4, 2023 /PRNewswire/ -- Byron Allen's Allen Media Group (AMG) proudly announces the hiring of Harold Morgenstern to the position of President of Direct Advertising Sales & Partnerships.
  • "Allen Media Group celebrates its 30th anniversary this year, and the addition of veteran ad sales executive Harold Morgenstern to our ad sales team will enhance the aggressive campaign to grow Allen Media Digital," said Byron Allen, Founder/Chairman/CEO of Allen Media Group.
  • "As massive growth continues within ad-supported digital and streaming platforms, I am excited to join Byron Allen and the Allen Media Group team," said Harold Morgenstern, President of Direct Advertising Sales & Partnerships.
  • "Better than any company I have ever seen, the Allen Media Digital portfolio is extremely well-positioned for exponential global growth."

Epicore Biosystems Unveils Connected Hydration Biowearable at CES 2023

Retrieved on: 
Wednesday, January 4, 2023
Chevron Corporation, Human, Climate change, Fatality, Hydration, Mining, Health, Partnership, Discovery, FDA, Safety, Consumer Electronics Show, Army of the United States, Athlete, Agriculture, CES, PepsiCo, Smart contract, Movement, Dehydration, Perspiration, Thermoregulation, Skin temperature, Cement, Gatorade

CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Epicore Biosystems, a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced that it will unveil its new Connected Hydration sweat patch and mobile app at the 2023 Consumer Electronics Show (CES) from Jan. 5-8. The first wearable to continuously measure sweat fluid and electrolyte losses while monitoring skin temperature and movement, Connected Hydration is designed for industrial athletes working on the frontlines of labor-intensive industries such as energy, clean tech, construction, mining, utilities, agriculture, trucking, warehouse packaging, and more. Through real-time alarms and vibrations onboard the device, Connected Hydration alerts wearers when their fluid loss exceeds 2% of body weight to prevent dehydration.

Key Points: 
  • , Jan. 4, 2023 /PRNewswire/ -- Epicore Biosystems , a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced that it will unveil its new Connected Hydration sweat patch and mobile app at the 2023 Consumer Electronics Show (CES) from Jan. 5-8.
  • Epicore Biosystems is introducing Connected Hydration and its advanced features at a critical time as climate change worsens, temperatures rise, and industrial working conditions intensify .
  • Epicore Biosystems will launch the patented Connected Hydration patch, mobile application, and cloud engine in summer 2023.
  • To learn more about Epicore Biosystems and its products, visit the 3M booth #9031 at CES 2023 and www.epicorebiosystems.com .